MedTrace Logo

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

NCT00441025 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2009-06-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether the treatment of Alemtuzumab in combination with CHOP(cyclophosphamide,doxorubicin,vincristine and prednisolone) are effective as first line treatment in patients with peripheral T-cell lymphoma.

Conditions

  • Peripheral T-Cell Lymphoma

Interventions

DRUG

Alemtuzumab

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Mahidol University

    lead OTHER

Principal Investigators

  • Surapol Issaragrisil, M.D.,Prof. · Siriraj Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2009-08-31

Countries

  • Thailand

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441025 on ClinicalTrials.gov